Dr. Moons Anke
ActiveSummary
Dr. Moons Anke has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €18,600 and a net result of €183,501. Equity has been shrinking by about 17% per year since 2019. If that trend continues, it turns negative around financial year 2027. The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 28-08-2018 Normal situation
- Activity
- “De uitoefening van de geneeskunde door de arts-aandeelhouders,zijnde meer in het bijzonder huisarts,in naam…” (deed in Dutch)From the articles, 14 activitiesNo NACE code in the KBO yet
- Establishment unit
- 2.279.241.860 3582 Beringen, since 28-08-2018
- Financial year end
- 31 December
- Peppol
- Reachable
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
- Gross margin
- €248,738
- ▲ 46.0%
- Turnover
- ≈ €620,000
- estimated
- Profit
- €183,501
- ▲ 46.2%
- Equity
- €18,600
- =
- Total assets
- €375,083
- ▼ 3.4%
Score breakdownraises riskEquity €18,600 (5.0% of total assets)lowers riskSize: total assets €375,083No main activity registeredLiquidity: current ratio 1.01, cash €317,164Show the evidence
Checked score
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro). It does better than 19% of them on solvency, 35% on liquidity, 90% on profitability and 47% on growth.
The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 1 day before the deadline. The Belgian median for financial year 2024 was 4 days before the deadline, and 38% of all filings were late.
Searched, nothing found (2)
Financials
Financials · financial year 2025, micro format
Annual accounts 2025 filed on 01-06-2026 PDF all 7 filings
Every figure per financial year
The operating result for 2025 is 47% higher than in 2024 and the highest since 2019. It is a recovery after the fall in 2024.
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Investments
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €8,000 | €3,388 | €6,500 | - | €5,475 |
| Financial fixed assets | - | €5,040 | - | - | - |
| Depreciation and write-downs of the year | €2,940 | €2,369 | €2,573 | €3,347 | €4,245 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €1,121 | €554 | €2,940 | €2,369 | €2,573 | €3,347 | €4,245 | ▲ 26.8% |
| Other operating charges640/8 | - | - | €1,059 | €1,030 | €783 | €882 | €816 | ▼ 7.5% |
| Gross operating margin9900 | €125,159 | €108,111 | €106,260 | €141,344 | €171,383 | €170,362 | €248,738 | ▲ 46.0% |
| Operating profit (loss)9901 | €121,965 | €106,500 | €102,261 | €137,945 | €168,027 | €166,133 | €243,677 | ▲ 46.7% |
| Financial income75/76B | - | - | €3 | €3 | €0 | €3,095 | €2,875 | ▼ 7.1% |
| Recurring financial income75 | €16 | - | €3 | €3 | €0 | €3,095 | €2,875 | ▼ 7.1% |
| Financial charges65/66B | - | - | €208 | €986 | €646 | €1,232 | €1,046 | ▼ 15.1% |
| Recurring financial charges65 | €49 | €276 | €208 | €986 | €646 | €1,232 | €1,046 | ▼ 15.1% |
| Profit (loss) for the period before taxes9903 | €121,932 | €106,225 | €102,056 | €136,961 | €167,381 | €167,996 | €245,506 | ▲ 46.1% |
| Income taxes67/77 | €27,642 | €22,063 | €21,053 | €34,691 | €35,606 | €42,483 | €62,005 | ▲ 46.0% |
| Profit (loss) for the period9904 | €94,290 | €84,162 | €81,003 | €102,270 | €131,775 | €125,513 | €183,501 | ▲ 46.2% |
| Profit (loss) for the period to be appropriated9905 | €94,290 | €84,162 | €81,003 | €102,270 | €131,775 | €125,513 | €183,501 | ▲ 46.2% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total assets20/58 | €141,360 | €227,255 | €283,438 | €388,097 | €377,215 | €388,118 | €375,083 | ▼ 3.4% |
| Fixed assets21/28 | €4,022 | €3,922 | €8,981 | €15,040 | €18,968 | €15,621 | €16,851 | ▲ 7.9% |
| Tangible fixed assets22/27 | €922 | €822 | €5,881 | €6,900 | €10,828 | €7,481 | €8,711 | ▲ 16.4% |
| Land and buildings22 | - | - | - | - | €1,449 | €1,149 | €849 | ▼ 26.1% |
| Plant, machinery and equipment23 | - | - | €279 | €204 | €129 | €54 | €2,791 | ▲ 52× |
| Furniture and vehicles24 | - | - | €5,602 | €6,696 | €9,249 | €6,278 | €5,071 | ▼ 19.2% |
| Financial fixed assets28 | €3,100 | €3,100 | €3,100 | €8,140 | €8,140 | €8,140 | €8,140 | = |
| Current assets29/58 | €137,338 | €223,334 | €274,457 | €373,056 | €358,247 | €372,497 | €358,232 | ▼ 3.8% |
| Amounts receivable within one year40/41 | - | €634 | €5,947 | €36,223 | €36,824 | - | - | - |
| Other amounts receivable41 | - | - | €5,947 | €36,223 | €36,824 | - | - | - |
| Cash at bank and in hand54/58 | €136,402 | €221,799 | €267,590 | €318,541 | €318,408 | €352,079 | €317,164 | ▼ 9.9% |
| Deferred charges and accrued income490/1 | - | - | €920 | €18,293 | €3,015 | €20,419 | €41,068 | ▲ 101% |
| Equity and liabilities | ||||||||
| Total equity and liabilities10/49 | €141,360 | €227,255 | €283,438 | €388,097 | €377,215 | €388,118 | €375,083 | ▼ 3.4% |
| Equity10/15 | €106,690 | €190,852 | €271,855 | €380,324 | €18,600 | €18,600 | €18,600 | = |
| Contributions10/11 | €12,400 | - | €12,400 | €18,600 | €18,600 | €18,600 | €18,600 | = |
| Reserves13 | €94,290 | €178,452 | €178,452 | €361,724 | - | - | - | - |
| Distributable reserves133 | - | - | €178,452 | €361,724 | - | - | - | - |
| Profit (loss) carried forward14 | - | - | €81,003 | - | - | - | - | - |
| Amounts payable17/49 | €34,670 | €36,404 | €11,584 | €7,773 | €358,615 | €369,518 | €356,483 | ▼ 3.5% |
| Amounts payable within one year42/48 | €34,670 | €36,404 | €11,584 | €7,773 | €358,615 | €369,249 | €356,126 | ▼ 3.6% |
| Trade debts44 | €2 | €931 | €171 | €81 | €722 | €926 | €891 | ▼ 3.7% |
| Suppliers440/4 | - | - | €171 | €81 | €722 | €926 | €891 | ▼ 3.7% |
| Taxes, remuneration and social security45 | - | - | €1,500 | €7,691 | €78,419 | €6,555 | €2,143 | ▼ 67.3% |
| Taxes450/3 | - | - | €1,500 | €7,691 | €77,419 | €6,555 | €2,143 | ▼ 67.3% |
| Remuneration and social security454/9 | - | - | - | - | €1,000 | - | - | - |
| Other amounts payable47/48 | - | - | €9,913 | - | €279,474 | €361,768 | €353,092 | ▼ 2.4% |
| Accrued charges and deferred income492/3 | - | - | - | - | - | €270 | €357 | ▲ 32.2% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €94,290 | €84,162 | €81,003 | €102,270 | €131,775 | €125,513 | €183,501 | ▲ 46.2% |
| + Depreciation and write-downs630 | €1,121 | €554 | €2,940 | €2,369 | €2,573 | €3,347 | €4,245 | ▲ 26.8% |
| Operating cash flow (approximation) | €95,411 | €84,716 | €83,943 | €104,639 | €134,348 | €128,860 | €187,745 | ▲ 45.7% |
| Investment in fixed assets (approximation) | - | -€454 | -€8,000 | -€8,428 | -€6,500 | €0 | -€5,475 | - |
| Change in cash | - | €85,396 | €45,792 | €50,951 | -€133 | €33,670 | -€34,915 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 2,153 companies had the same profile as Dr. Moons Anke has now. Two years later, 96.1% were still going and 1.7% had gone bankrupt.
- Micro
- 5 to 10 years old
- solvency under 10%
- a profit of 5% of the balance sheet or more
The bankruptcy probability of Dr. Moons Anke itself is lower: 0.1% within 12 months. It rests on far more data about Dr. Moons Anke than the profile alone.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,153 companies, not a prediction for Dr. Moons Anke. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Filings with the National Bank (7)
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | micro format | 01-06-2026 | 2026-00128772 | |
| 31-12-2024 | micro format | 09-07-2025 | 2025-00247270 | |
| 31-12-2023 | micro format | 29-08-2024 | 2024-00390914 | |
| 31-12-2022 | micro format | 24-08-2023 | 2023-00347274 | |
| 31-12-2021 | micro format | 25-08-2022 | 2022-20315045 | |
| 31-12-2020 | micro format | 13-07-2021 | 2021-35100007 | |
| 31-12-2019 | micro format | 12-08-2020 | 2020-40800501 |
Board & ownership
Directors
Owners and capital
Capital transactions
- 20-09-2023 Converted to unavailable equity · €18,600
Mandate history
- Board
- mandate already running before its first mention
| Name | Functions and periods |
|---|---|
| MOONS Anke |
|
Articles of association
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At least 1 director
Articles of association, deed of 20-09-2023 (in Dutch)
Network & group
Dr. Moons Anke shares no director with another company.
Connections & network
1 current directorThe network starts from the directors of Dr. Moons Anke. Every other company they run is a node.
Timeline
Deeds, filings and financial milestones
20-09
Gazette deed
Change of role: MOONS Anke, from manager to director“De uitoefening van de geneeskunde door de arts-aandeelhouders,zijnde meer in het bijzonder huisarts,in naam en…” (deed in Dutch)6 points ▸
- General meeting, 06-09-2023
- 100 shares
- Director resignation, MOONS Anke (manager)
- Director appointment, MOONS Anke (director (not named in the articles))
- Registered office clause, Kruisvijverstraat 14
- Power of attorney, Yves DE CEUNYNCK
- The deed holds 4 more points.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordRegistered office and establishments
Activities
14 activities
- De uitoefening van de geneeskunde door de arts-aandeelhouders,zijnde meer in het bijzonder huisarts,in naam en voor rekening van de vennootschap,met inachtname van de regels van de medische deontologie.
- De geneeskunde wordt uitgeoefend onder de specifieke beroepsaansprakelijkheid van de aandeelhouders en de bijkomende aansprakelijkheid van de vennootschap.
- De activiteit omvat impliciet de inning van de erelonen door en voor de vennootschap en de betaling aan de arts-aandeelhouder van een vergoeding in verhouding tot de prestatie die hij voor rekening van de vennootschap geleverd heeft.
- Het ter beschikking stellen van alle nodige middelen aan de arts/artsen die tot de vennootschap zijn toegetreden;het inrichten van algemene diensten en een medisch secretariaat in het bijzonder,die nuttig of nodig zijn voor de uitoefening van voornoemde activiteiten.
- De aankoop,het huren en/of leasen van alle medische apparatuur en begeleidende accommodaties,inclusief gebouwen,kortom van een volledige materiële infrastructuur om deze ter beschikking te stellen van de arts-aandeelhouder voor de voornoemde activiteiten.
- Mits inachtname van de Code Medische Deontologie,mag de vennootschap alle onroerende en roerende verrichtingen uitvoeren die van aard zijn rechtstreeks of onrechtstreeks de verwezenlijking van haar voorwerp te bevorderen,te vergemakkelijken of te begunstigen.
- Het aanleggen van reserves teneinde alle nodige apparaten en gebouwen aan te schaffen,nodig of nuttig om voornoemd voorwerp te bereiken,evenals het beheer van deze reserves als een goed huisvader.
- De mogelijkheid scheppen om de arts-aandeelhouder of arts-aandeelhouders toe te laten zich verder te bekwamen ten einde in hun discipline aan de spits van de evolutie te blijven.
- De artsen-aandeelhouders die allen ingeschreven dienen te zijn op de Lijst van de Orde der Artsen en die hun beroep op actieve wijze dienen uit te oefenen,verbinden er zich toe hun volledige medische activiteit in de vennootschap te brengen en alle daaruit voortvloeiende honoraria zullen geïnd worden door en voor de vennootschap.
- De vennootschap mag overeenkomsten afsluiten met en samenwerken met alle verenigingen,rechtspersonen en vennootschappen die een gelijkaardig voorwerp nastreven of die bijdragen tot de algehele of gedeeltelijke verwezenlijking van het voorwerp.
- De aandeelhouders zullen steeds de Medische Deontologie van de Orde der Artsen naleven.
- Overeenkomsten die artsen omwille van deontologische redenen niet mogen afsluiten mogen evenmin door de vennootschap worden afgesloten.
- De vennootschap kan enkel toetreden tot een(kosten)associatie,een middelenvennootschap of een vzw.
- De vennootschap kan als bijkomstig voorwerp alle roerende en onroerende goederen en rechten verwerven en beheren en rechtshandelingen dienaangaande stellen,zonder dat deze activiteit een regelmatig en commercieel karakter mag krijgen,en indien tussen de aandeelhouders een voorafgaandelijk akkoord over de investeringsmodaliteiten met ten minste een 2/3de meerderheid schriftelijk wordt vastgelegd.
Invoicing and payment
Financial year and general meeting
Accounts at the NBBSites & property
Buildings and parcels at the addresses
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 71029B0490/00D000 | Flanders | 3,056 m² | 1 · 286 m² | 7.1 m · 2 |
| 71025A1561/00M003 | Flanders | 963 m² | 1 · 123 m² | 15.4 m · 2 |